These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
970 related articles for article (PubMed ID: 24496003)
1. HIP1-ALK, a novel ALK fusion variant that responds to crizotinib. Fang DD; Zhang B; Gu Q; Lira M; Xu Q; Sun H; Qian M; Sheng W; Ozeck M; Wang Z; Zhang C; Chen X; Chen KX; Li J; Chen SH; Christensen J; Mao M; Chan CC J Thorac Oncol; 2014 Mar; 9(3):285-94. PubMed ID: 24496003 [TBL] [Abstract][Full Text] [Related]
2. Identification of a novel HIP1-ALK fusion variant in Non-Small-Cell Lung Cancer (NSCLC) and discovery of ALK I1171 (I1171N/S) mutations in two ALK-rearranged NSCLC patients with resistance to Alectinib. Ou SH; Klempner SJ; Greenbowe JR; Azada M; Schrock AB; Ali SM; Ross JS; Stephens PJ; Miller VA J Thorac Oncol; 2014 Dec; 9(12):1821-5. PubMed ID: 25393796 [TBL] [Abstract][Full Text] [Related]
3. ALK inhibitors in the treatment of advanced NSCLC. Gridelli C; Peters S; Sgambato A; Casaluce F; Adjei AA; Ciardiello F Cancer Treat Rev; 2014 Mar; 40(2):300-6. PubMed ID: 23931927 [TBL] [Abstract][Full Text] [Related]
4. HIP1-ALK, a novel fusion protein identified in lung adenocarcinoma. Hong M; Kim RN; Song JY; Choi SJ; Oh E; Lira ME; Mao M; Takeuchi K; Han J; Kim J; Choi YL J Thorac Oncol; 2014 Mar; 9(3):419-22. PubMed ID: 24518094 [TBL] [Abstract][Full Text] [Related]
5. A new human lung adenocarcinoma cell line harboring the EML4-ALK fusion gene. Isozaki H; Yasugi M; Takigawa N; Hotta K; Ichihara E; Taniguchi A; Toyooka S; Hashida S; Sendo T; Tanimoto M; Kiura K Jpn J Clin Oncol; 2014 Oct; 44(10):963-8. PubMed ID: 25170107 [TBL] [Abstract][Full Text] [Related]
6. Clinical outcomes in ALK-rearranged lung adenocarcinomas according to ALK fusion variants. Cha YJ; Kim HR; Shim HS J Transl Med; 2016 Oct; 14(1):296. PubMed ID: 27756333 [TBL] [Abstract][Full Text] [Related]
7. Rearranged EML4-ALK fusion transcripts sequester in circulating blood platelets and enable blood-based crizotinib response monitoring in non-small-cell lung cancer. Nilsson RJ; Karachaliou N; Berenguer J; Gimenez-Capitan A; Schellen P; Teixido C; Tannous J; Kuiper JL; Drees E; Grabowska M; van Keulen M; Heideman DA; Thunnissen E; Dingemans AM; Viteri S; Tannous BA; Drozdowskyj A; Rosell R; Smit EF; Wurdinger T Oncotarget; 2016 Jan; 7(1):1066-75. PubMed ID: 26544515 [TBL] [Abstract][Full Text] [Related]
8. Clinicopathological features and resistance mechanisms in HIP1-ALK-rearranged lung cancer: A multicenter study. Kang J; Deng QM; Peng KC; Li P; Zhu BT; Wang P; Chu XP; Zhong WZ; Chen HJ; Wang WX; Chen HF; Rao CZ; Xu CW; Yang JJ Genes Chromosomes Cancer; 2022 Apr; 61(4):177-186. PubMed ID: 34687488 [TBL] [Abstract][Full Text] [Related]
9. Differential protein stability and clinical responses of EML4-ALK fusion variants to various ALK inhibitors in advanced ALK-rearranged non-small cell lung cancer. Woo CG; Seo S; Kim SW; Jang SJ; Park KS; Song JY; Lee B; Richards MW; Bayliss R; Lee DH; Choi J Ann Oncol; 2017 Apr; 28(4):791-797. PubMed ID: 28039177 [TBL] [Abstract][Full Text] [Related]
10. Targeting stemness is an effective strategy to control EML4-ALK+ non-small cell lung cancer cells. Oh SJ; Noh KH; Lee YH; Hong SO; Song KH; Lee HJ; Kim S; Kim TM; Jeon JH; Seo JH; Kim DW; Kim TW Oncotarget; 2015 Nov; 6(37):40255-67. PubMed ID: 26517679 [TBL] [Abstract][Full Text] [Related]
11. Anaplastic lymphoma kinase rearrangement in lung cancer: its biological and clinical significance. Toyokawa G; Seto T Respir Investig; 2014 Nov; 52(6):330-8. PubMed ID: 25453376 [TBL] [Abstract][Full Text] [Related]
12. Development of potent ALK inhibitor and its molecular inhibitory mechanism against NSCLC harboring EML4-ALK proteins. Kang CH; Yun JI; Lee K; Lee CO; Lee HK; Yun CS; Hwang JY; Cho SY; Jung H; Kim P; Ha JD; Jeon JH; Choi SU; Jeong HG; Kim HR; Park CH Biochem Biophys Res Commun; 2015 Aug; 464(3):762-7. PubMed ID: 26168728 [TBL] [Abstract][Full Text] [Related]
13. Detection of ALK rearrangement by immunohistochemistry in lung adenocarcinoma and the identification of a novel EML4-ALK variant. To KF; Tong JH; Yeung KS; Lung RW; Law PP; Chau SL; Kang W; Tong CY; Chow C; Chan AW; Leung LK; Mok TS J Thorac Oncol; 2013 Jul; 8(7):883-91. PubMed ID: 23625156 [TBL] [Abstract][Full Text] [Related]
14. Exon array profiling detects EML4-ALK fusion in breast, colorectal, and non-small cell lung cancers. Lin E; Li L; Guan Y; Soriano R; Rivers CS; Mohan S; Pandita A; Tang J; Modrusan Z Mol Cancer Res; 2009 Sep; 7(9):1466-76. PubMed ID: 19737969 [TBL] [Abstract][Full Text] [Related]
15. An Anaplastic Lymphoma Kinase Immunohistochemistry-Negative but Fluorescence In Situ Hybridization-Positive Lung Adenocarcinoma Is Resistant to Crizotinib. Shi R; Varella-Garcia M; Li M; Ludkovski O; Danesh A; Ng C; Pham NA; Pugh T; Shepherd FA; Tsao MS J Thorac Oncol; 2016 Dec; 11(12):2248-2252. PubMed ID: 27613526 [TBL] [Abstract][Full Text] [Related]
16. EML4-ALK Fusion Detected by RT-PCR Confers Similar Response to Crizotinib as Detected by FISH in Patients with Advanced Non-Small-Cell Lung Cancer. Wang Y; Zhang J; Gao G; Li X; Zhao C; He Y; Su C; Zhang S; Chen X; Zhang J; Li W; Li B; Zhao J; Hou L; Wu C; Ren S; Zhou C; Zhang J J Thorac Oncol; 2015 Nov; 10(11):1546-52. PubMed ID: 26352533 [TBL] [Abstract][Full Text] [Related]
17. New insights into anaplastic lymphoma kinase-positive nonsmall cell lung cancer. Dubey AP; Pathi N; Viswanath S; Rathore A; Pathak A; Sud R Indian J Cancer; 2017; 54(1):203-208. PubMed ID: 29199691 [TBL] [Abstract][Full Text] [Related]
18. Comparison of reverse transcription-polymerase chain reaction, immunohistochemistry, and fluorescence in situ hybridization methodologies for detection of echinoderm microtubule-associated proteinlike 4-anaplastic lymphoma kinase fusion-positive non-small cell lung carcinoma: implications for optimal clinical testing. Wallander ML; Geiersbach KB; Tripp SR; Layfield LJ Arch Pathol Lab Med; 2012 Jul; 136(7):796-803. PubMed ID: 22742552 [TBL] [Abstract][Full Text] [Related]
19. Comprehensive Genomic Profiling Identifies a Subset of Crizotinib-Responsive ALK-Rearranged Non-Small Cell Lung Cancer Not Detected by Fluorescence In Situ Hybridization. Ali SM; Hensing T; Schrock AB; Allen J; Sanford E; Gowen K; Kulkarni A; He J; Suh JH; Lipson D; Elvin JA; Yelensky R; Chalmers Z; Chmielecki J; Peled N; Klempner SJ; Firozvi K; Frampton GM; Molina JR; Menon S; Brahmer JR; MacMahon H; Nowak J; Ou SH; Zauderer M; Ladanyi M; Zakowski M; Fischbach N; Ross JS; Stephens PJ; Miller VA; Wakelee H; Ganesan S; Salgia R Oncologist; 2016 Jun; 21(6):762-70. PubMed ID: 27245569 [TBL] [Abstract][Full Text] [Related]
20. Therapeutic strategies to overcome crizotinib resistance in non-small cell lung cancers harboring the fusion oncogene EML4-ALK. Katayama R; Khan TM; Benes C; Lifshits E; Ebi H; Rivera VM; Shakespeare WC; Iafrate AJ; Engelman JA; Shaw AT Proc Natl Acad Sci U S A; 2011 May; 108(18):7535-40. PubMed ID: 21502504 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]